The notices it replaced
- Reissues: PAR-23-125 Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
- Reissues: PAR-25-261 NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
- 2 steps back: PAR-20-224 Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)
- 2 steps back: PAR-23-269 NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
- 3 steps back: PAR-20-221 NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)
- 3 steps back: RFA-DA-18-004 Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)
- 4 steps back: RFA-DA-15-007 Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)
- 4 steps back: RFA-DA-18-019 NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)
- 5 steps back: RFA-DA-18-001 NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1)
- 6 steps back: RFA-DA-15-004 NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1)
- 7 steps back: RFA-DA-14-008 FY14 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 8 steps back: RFA-DA-13-002 FY13 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 9 steps back: RFA-DA-12-011 FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 10 steps back: RFA-DA-11-002 2011 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 11 steps back: RFA-DA-10-012 2010 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 12 steps back: RFA-DA-09-011 2009 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 13 steps back: RFA-DA-08-003
Who won it before
61 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $96,339,022 in first-year total cost, median $1,210,300.
Most frequent study sections
- Special Emphasis Panel[ZDA1 HXO-H (08)]9
- Special Emphasis Panel[ZDA1 SKP-X (J1)]8
- Special Emphasis Panel[ZDA1 PXN-F (06)]7
- Special Emphasis Panel[ZDA1 HXO-H (10)]6
- Special Emphasis Panel[ZDA1 GXM-A (04)]5
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL5
- UNIVERSITY OF CALIFORNIA, SAN DIEGO4
- JOHNS HOPKINS UNIVERSITY3
- UNIVERSITY OF MIAMI SCHOOL OF MEDICINE3
- UNIVERSITY OF WASHINGTON3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Enhancing Access to Timely Research to Prevent HIV Transmission and Effectively Treat Substance Use1DP2DA063114-01 · under PAR-23-125 | CRABLE, ERIKA LYNN | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $2,362,500 | ZDA1 |
| 2025 | Transforming systems of care to address HIV, HIV risk, and substance use disorders in prisons1DP2DA063100-01 · under PAR-23-125 | JACK, HELEN ELIZABETH | UNIVERSITY OF WASHINGTON, WA | $2,332,500 | ZDA1 |
| 2025 | Community-Based Opioid Treatment (CBOT): Development and testing of a novel nurse-led model to deliver opioid use disorder treatment and HIV prevention and care in the community setting.1DP2DA063123-01 · under PAR-23-125 | HEIDARI, OMEID | UNIVERSITY OF WASHINGTON, WA | $2,332,500 | ZDA1 |
| 2025 | HIV vaccine swarms for PWID1DP1DA063166-01 · under PAR-23-269 | PENALOZA-MACMASTER, PABLO | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,210,300 | ZDA1 |
| 2024 | Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV1DP2DA060600-01 · under PAR-23-125 | APPA, AYESHA A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $2,460,000 | ZDA1 |
| 2024 | Polyclonal Bi-Specific Vectored ImmunoTherapy to Functionally Cure HIV Infection1DP1DA060607-01 · under PAR-23-269 | BALAZS, ALEJANDRO BENJAMIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,052,100 | ZDA1 |
| 2024 | Long-Acting Injectables for Treatment of HIV among PWID (LIFT HIV)1DP1DA060602-01 · under PAR-23-269 | SOLOMON, SUNIL SUHAS | JOHNS HOPKINS UNIVERSITY, MD | $991,463 | ZDA1 |
| 2024 | Engineering Bacteriophage T4 as a Targeted Gene Therapy Drug for in vivo HIV Cure1DP1DA060580-01 · under PAR-23-269 | RAO, VENIGALLA B. | CATHOLIC UNIVERSITY OF AMERICA, DC | $964,530 | ZDA1 |
| 2023 | ENTRUST - economic navigation and strengthening to realize unrestricted services for transgender women1DP2DA058436-01 · under PAR-20-224 | CYRUS, ELENA | UNIVERSITY OF CENTRAL FLORIDA, FL | $2,280,000 | ZDA1 |
| 2023 | Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV Cure1DP1DA058476-01 · under PAR-20-221 | GAIHA, GAURAV DAS | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,169,000 | ZDA1 |
| 2022 | Smart Steps: A context-aware adherence intervention to improve PrEP adherence among men who have sex with men (MSM) with substance use disorder1DP2DA056107-01 · under PAR-20-224 | CHAI, PETER R | BRIGHAM AND WOMEN'S HOSPITAL, MA | $2,685,000 | ZDA1 |
| 2022 | Immune Network Dysregulation of the Central Nervous System with HIV Persistence and Opioid Abuse1DP2DA056169-01 · under PAR-20-224 | ZHANG, LE | YALE UNIVERSITY, CT | $2,512,500 | ZDA1 |
| 2022 | Molecular Networks and Deep Learning for Targeted HIV Interventions among PWID1DP2DA056130-01 · under PAR-20-224 | CLIPMAN, STEVEN J. | JOHNS HOPKINS UNIVERSITY, MD | $2,456,250 | ZDA1 |
| 2022 | Looking into the Heart of Cannabis and HIV1DP2DA056065-01 · under PAR-20-224 | MARTINEZ, CLAUDIA | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $2,302,500 | ZDA1 |
| 2022 | Single Chromatin Fiber Sequencing and Longitudinal Epigenomic Profiling in HIV+ Brain Cells Exposed to Narcotic and Stimulant1DP1DA056018-01 · under PAR-20-221 | AKBARIAN, SCHAHRAM | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,183,000 | ZDA1 |
| 2022 | Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live1DP1DA056106-01 · under PAR-20-221 | SPRINGER, SANDRA ANN | YALE UNIVERSITY, CT | $1,172,500 | ZDA1 |
| 2022 | HIV and Cocaine Drive Bone-Marrow Blood (BMB) Barrier Dysfunction and Altered Hematopoietic Stem Cell (HSC) Differentiation Leading to Cardiovascular Disease1DP2DA056172-01 · under PAR-20-224 | ANDREWS, ALLISON MICHELLE | TEMPLE UNIV OF THE COMMONWEALTH, PA | $570,030 | ZDA1 |
| 2021 | Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject Drugs1DP2DA053730-01 · under PAR-20-224 | AKIYAMA, MATTHEW | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $2,520,000 | ZDA1 |
| 2021 | Tele-Harm Reduction for Rapid Initiation of Antiretrovirals in People who Inject Drugs: a Randomized Controlled Trial1DP2DA053720-01 · under PAR-20-224 | TOOKES, HANSEL EMORY | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $2,302,500 | ZDA1 |
| 2021 | Defining the impact of drug use on immune function and fitness against HIV-11DP1DA053731-01 · under PAR-20-221 | SHALEK, ALEX K | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,176,000 | ZDA1 |
| 2021 | MR-guided focused ultrasound to eradicate CNS viral reservoirs and promote neurogenesis in the HIV-infected brain1DP1DA053719-01 · under PAR-20-221 | CHANG, LINDA | UNIVERSITY OF MARYLAND BALTIMORE, MD | $1,081,500 | ZDA1 |
| 2020 | Interferon-modulated vaccines against HIV1DP2DA051912-01 · under RFA-DA-18-004 | PENALOZA, PABLO | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $2,391,250 | ZDA1 |
| 2020 | The HIV-associated Opioid Micro-Environment (HOME) Project1DP2DA051915-01 · under RFA-DA-18-004 | GIANELLA WEIBEL, SARA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $2,368,125 | ZDA1 |
| 2020 | Pont-of-use Acute HIV Infection Diagnostic for Substance Using Populations1DP2DA051910-01 · under RFA-DA-18-004 | LINNES, JACQUELINE | PURDUE UNIVERSITY, IN | $2,325,000 | ZDA1 |
| 2020 | Integrating preclinical models to develop converging mechanistic data in co-occurring HIV and substance use1DP2DA051907-01 · under RFA-DA-18-004 | BARKER, JACQUELINE M | DREXEL UNIVERSITY, PA | $2,270,625 | ZDA1 |
| 2020 | A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups1DP1DA051144-01 · under RFA-DA-18-019 | WEINBERGER, LEOR S | J. DAVID GLADSTONE INSTITUTES, CA | $945,000 | ZDA1 |
| 2020 | HIV-CRISPR: A novel approach to the comprehensive discovery of HIV latency factors1DP1DA051110-01 · under RFA-DA-18-019 | EMERMAN, MICHAEL | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $880,000 | ZDA1 |
| 2020 | Development of a novel community-based high-performance surveillance network for drug use1DP2DA051864-01 · under RFA-DA-18-004 | BAROCAS, JOSHUA ADAM | BOSTON MEDICAL CENTER, MA | $77,554 | ZDA1 |
| 2019 | Novel, Adaptive Approaches to Predicting and Responding to Outbreaks of Overdose, HIV and HCV Among People Who Use Drugs1DP2DA049282-01 · under RFA-DA-18-004 | GONSALVES, GREGG STEVEN | YALE UNIVERSITY, CT | $2,512,500 | ZDA1 |
| 2019 | Real-time prediction of emerging drug use epidemics in the United States1DP2DA049295-01 · under RFA-DA-18-004 | BORQUEZ, ANNICK | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $2,367,000 | ZDA1 |
| 2019 | uTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM1DP2DA049296-01 · under RFA-DA-18-004 | HOLLOWAY, IAN WALTER | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $2,340,000 | ZDA1 |
| 2019 | DELINEATION AND VULNERABILITIES OF HIV-1 ESCAPE FROM NEUTRALIZING ANTIBODIES1DP2DA049279-01 · under RFA-DA-18-004 | HERSCHHORN, ALON | UNIVERSITY OF MINNESOTA, MN | $2,310,000 | ZDA1 |
| 2019 | Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia1DP1DA048570-01 · under RFA-DA-18-019 | ALBARRACIN, DOLORES | UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, IL | $793,000 | ZDA1 |
| 2019 | Contribution of the Virome to HIV/AIDS pathogenesis1DP1DA048493-01 · under RFA-DA-18-019 | KORALNIK, IGOR J. | RUSH UNIVERSITY MEDICAL CENTER, IL | $67,727 | ZDA1 |
| 2018 | Causal Inference Methods for HIV Prevention Studies Among Networks of People Who Use Drugs1DP2DA046856-01 · under RFA-DA-18-004 | BUCHANAN, ASHLEY LYNN | UNIVERSITY OF RHODE ISLAND, RI | $2,080,476 | ZDA1 |
| 2018 | Therapeutic Dendritic Cell Vaccine for HIV1DP1DA046100-01 · under RFA-DA-18-001 | LANDAU, NATHANIEL R. | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $847,500 | ZDA1 |
| 2018 | Targeting natural killer cells to HIV in intravenous drug users1DP1DA046089-01 · under RFA-DA-18-001 | BLISH, CATHERINE A | STANFORD UNIVERSITY, CA | $785,000 | ZDA1 |
| 2018 | Hunting the HIV-1 Unicorn1DP1DA046108-01 · under RFA-DA-18-001 | SAWYER, SARA | UNIVERSITY OF COLORADO, CO | $770,000 | ZDA1 |
| 2017 | Understanding the overlap of chromatin alteration in HIV-1 and drug abuse1DP2DA044550-01 · under RFA-DA-15-007 | KLASE, ZACHARY ALAN | UNIVERSITY OF THE SCIENCES PHILADELPHIA, PA | $1,274,854 | ZDA1 |
| 2017 | A safety switch for an effective HIV-1 vaccine1DP1DA043912-01 · under RFA-DA-15-004 | FARZAN, MICHAEL R. | SCRIPPS FLORIDA, FL | $960,000 | ZDA1 |
| 2017 | Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery1DP1DA043893-01 · under RFA-DA-15-004 | KIM, PETER S | STANFORD UNIVERSITY, CA | $785,000 | ZDA1 |
| 2017 | Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses1DP1DA043915-01 · under RFA-DA-15-004 | POESCHLA, ERIC M. | UNIVERSITY OF COLORADO DENVER, CO | $777,500 | ZDA1 |
| 2016 | Defining and Exploiting a Genetic Template for an HIV Vaccine1DP2DA042422-01 · under RFA-DA-15-007 | LINGWOOD, DANIEL | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,565,000 | ZDA1 |
| 2016 | Reaching the hardest of the hard-to-reach1DP2DA040244-01 · under RFA-DA-15-007 | SOLOMON, SUNIL SUHAS | JOHNS HOPKINS UNIVERSITY, MD | $2,430,000 | ZDA1 |
| 2016 | A New Approach to Integrating Primary and Secondary HIV Prevention in Young Male Couples1DP2DA042417-01 · under RFA-DA-15-007 | NEWCOMB, MICHAEL E | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $2,317,500 | ZDA1 |
| 2016 | Optimizing HIV care for patients with substance use disorders using predictive analytics in a mobile health application1DP2DA042424-01 · under RFA-DA-15-007 | WESTERGAARD, RYAN PATRICK | UNIVERSITY OF WISCONSIN-MADISON, WI | $2,295,000 | ZDA1 |
| 2016 | Functional Testing of Host Genes that control HIV Latency in Primary Immune Cells1DP2DA042423-01 · under RFA-DA-15-007 | MARSON, ALEXANDER | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $2,195,087 | ZDA1 |
| 2016 | Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse1DP1DA041722-01 · under RFA-DA-15-004 | LIPTON, STUART A | SCINTILLON INSTITUTE FOR PHOTOBIOLOGY, CA | $945,000 | ZDA1 |
| 2015 | Engineering Humoral Immunity to Functionally Cure HIV Infection1DP2DA040254-01 · under RFA-DA-15-007 | BALAZS, ALEJANDRO BENJAMIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,610,000 | ZDA1 |
| 2015 | Highly Adaptive Epidemic Control Strategies for HIV Prevention in Drug Users1DP2DA040236-01 · under RFA-DA-15-007 | MARSHALL, BRANDON DAVID LEWIS | BROWN UNIVERSITY, RI | $2,437,500 | ZDA1 |
| 2015 | Decision Making and HIV Risk: New Approaches to neuroAIDS Research in Drug Users1DP2DA040226-01 · under RFA-DA-15-007 | MEADE, CHRISTINA S | DUKE UNIVERSITY, NC | $2,385,000 | ZDA1 |
| 2015 | Preventing HIV by modifying the context for injecting initiation1DP2DA040256-01 · under RFA-DA-15-007 | WERB, DANIEL M | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $2,325,000 | ZDA1 |
| 2015 | Impact of Cannabis on Inflammation and Viral Persistence in Treated HIV/SIV1DP1DA037979-01 · under RFA-DA-14-008 | KLATT, NICHOLE ROSE | UNIVERSITY OF WASHINGTON, WA | $890,000 | ZDA1 |
| 2015 | TOWARDS A MORE RELEVANT MODEL OF HIV INFECTION1DP1DA039543-01 · under RFA-DA-15-004 | OVERBAUGH, JULIE M. | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $880,000 | ZDA1 |
| 2015 | Repairing the intestinal epithelium from the dual action of HIV and drug use1DP1DA037997-01 · under RFA-DA-14-008 | LEVINE, ALAN DAVID | CASE WESTERN RESERVE UNIVERSITY, OH | $792,500 | ZDA1 |
| 2015 | Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells1DP1DA039562-01 · under RFA-DA-15-004 | RANA, TARIQ M | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $775,000 | ZDA1 |
| 2015 | Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs1DP1DA039560-01 · under RFA-DA-15-004 | GILBOA, ELI | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $767,500 | ZDA1 |
| 2015 | Combined prevention to reduce initiation into injecting drug use1DP1DA039542-01 · under RFA-DA-15-004 | DES JARLAIS, DON C | BETH ISRAEL MEDICAL CTR (NEW YORK), NY | $112,067 | ZDA1 |
| 2014 | A new model of accelerated immune aging in HIV-infected drug users1DP1DA038043-01 · under RFA-DA-14-008 | OTT, MELANIE MARIA | J. DAVID GLADSTONE INSTITUTES, CA | $955,000 | ZDA1 |
| 2014 | Mechanism of HIV Cell-Cell Transmission of Relevance to Substance Users1DP1DA038034-01 · under RFA-DA-14-008 | GOTTLINGER, HEINRICH | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $837,084 | ZDA1 |
| 2014 | A revolutionary vaccine approach to prevent HIV infection in substance abuse1DP1DA038017-01 · under RFA-DA-14-008 | WAGGONER, STEPHEN N. | CINCINNATI CHILDRENS HOSP MED CTR, OH | $780,000 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.